{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:51:18Z","timestamp":1790783478261,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002261","name":"Russian Foundation for Basic Research","doi-asserted-by":"publisher","award":["18-29-07033"],"award-info":[{"award-number":["18-29-07033"]}],"id":[{"id":"10.13039\/501100002261","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1038\/s41434-020-0141-0","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T21:07:22Z","timestamp":1584047242000},"page":"247-253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Reactivation of FMR1 gene expression is a promising strategy for fragile X syndrome therapy"],"prefix":"10.1038","volume":"27","author":[{"given":"Ekaterina M.","family":"Shitik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia A.","family":"Velmiskina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander A.","family":"Dolskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8940-9173","authenticated-orcid":false,"given":"Dmitry V.","family":"Yudkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,12]]},"reference":[{"key":"141_CR1","doi-asserted-by":"crossref","first-page":"17065","DOI":"10.1038\/nrdp.2017.65","volume":"3","author":"RJ Hagerman","year":"2017","unstructured":"Hagerman RJ, Berry-Kravis E, Hazlett HC, Bailey DB, Moine H, Kooy RF, et al. Fragile X syndrome. Nat Rev Dis Primers. 2017;3:17065.","journal-title":"Nat Rev Dis Primers."},{"key":"141_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnmol.2018.00282","volume":"11","author":"JM Haenfler","year":"2018","unstructured":"Haenfler JM, Skariah G, Rodriguez CM, Monteiro da Rocha A, Parent JM, Smith GD, et al. Targeted reactivation of FMR1 transcription in fragile X syndrome embryonic stem cells. Front Mol Neurosci. 2018;11:1\u201317.","journal-title":"Front Mol Neurosci."},{"key":"141_CR3","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/00125817-200105000-00010","volume":"3","author":"A Maddalena","year":"2001","unstructured":"Maddalena A, Richards CS, McGinniss MJ, Brothman A, Desnick RJ, Grier RE, et al. Technical standards and guidelines for fragile X: the first of a series of disease-specific supplements to the standards and guidelines for clinical genetics laboratories of the American College of Medical Genetics. Genet Med. 2001;3:200\u20135.","journal-title":"Genet Med."},{"key":"141_CR4","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/14737159.2017.1377612","volume":"17","author":"P Jiraanont","year":"2017","unstructured":"Jiraanont P, Kumar M, Tang HT, Espinal G, Hagerman PJ, Hagerman RJ, et al. Size and methylation mosaicism in males with fragile X syndrome. Expert Rev Mol Diagn. 2017;17:1023\u201332.","journal-title":"Expert Rev Mol Diagn."},{"key":"141_CR5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12519-015-0052-0","volume":"12","author":"SY Luo","year":"2016","unstructured":"Luo SY, Wu LQ, Duan RH. Molecular medicine of fragile X syndrome: based on known molecular mechanisms. World J Pediatr. 2016;12:19\u201327.","journal-title":"World J Pediatr."},{"key":"141_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/genes7080049","volume":"7","author":"E Tabolacci","year":"2016","unstructured":"Tabolacci E, Palumbo F, Nobile V, Neri G. Transcriptional reactivation of the FMR1 gene. A possible approach to the treatment of the fragile X syndrome. Genes. 2016;7:1\u201316.","journal-title":"Genes."},{"key":"141_CR7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrg3863","volume":"16","author":"D Holoch","year":"2015","unstructured":"Holoch D, Moazed D. RNA-mediated epigenetic regulation of gene expression. Nat Rev Genet. 2015;16:71\u201384.","journal-title":"Nat Rev Genet."},{"key":"141_CR8","first-page":"1","volume":"11","author":"N Xie","year":"2016","unstructured":"Xie N, Gong H, Suhl JA, Chopra P, Wang T, Warren ST. Reactivation of FMR1 by CRISPR\/Cas9-mediated deletion of the expanded CGG-repeat of the fragile X chromosome. PLoS One. 2016;11:1\u201312.","journal-title":"PLoS One."},{"key":"141_CR9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.celrep.2015.08.084","volume":"13","author":"CY Park","year":"2015","unstructured":"Park CY, Halevy T, Lee DR, Sung JJ, Lee JS, Yanuka O, et al. Reversion of FMR1 methylation and silencing by editing the triplet repeats in fragile X iPSC-derived neurons. Cell Rep. 2015;13:234\u201341.","journal-title":"Cell Rep."},{"key":"141_CR10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0269881117741766","volume":"32","author":"OD Howes","year":"2018","unstructured":"Howes OD, Group EPF, Rogdaki M, Findon JL, Wichers RH, Charman T, et al. Autism spectrum disorder: consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. J Psychopharmacol. 2018;32:3\u201329.","journal-title":"J Psychopharmacol."},{"key":"141_CR11","doi-asserted-by":"crossref","first-page":"7746","DOI":"10.1073\/pnas.122205699","volume":"99","author":"KM Huber","year":"2002","unstructured":"Huber KM, Gallagher SM, Warren ST, Bear MF. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci. 2002;99:7746\u201350.","journal-title":"Proc Natl Acad Sci."},{"key":"141_CR12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.neuropharm.2016.12.010","volume":"116","author":"V Sabanov","year":"2017","unstructured":"Sabanov V, Braat S, D\u2019Andrea L, Willemsen R, Zeidler S, Rooms L, et al. Impaired GABAergic inhibition in the hippocampus of Fmr1 knockout mice. Neuropharmacology. 2017;116:71\u201381.","journal-title":"Neuropharmacology."},{"key":"141_CR13","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.4161\/15384101.2014.989114","volume":"14","author":"S Braat","year":"2015","unstructured":"Braat S, D\u2019Hulst C, Heulens I, de Rubeis S, Mientjes E, Nelson DL, et al. The GABAA receptor is an FMRP target with therapeutic potential in fragile X syndrome. Cell Cycle. 2015;14:2985\u201395.","journal-title":"Cell Cycle."},{"key":"141_CR14","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.neuroimage.2019.02.051","volume":"191","author":"V Zerbi","year":"2019","unstructured":"Zerbi V, Markicevic M, Gasparini F, Schroeter A, Rudin M, Wenderoth N. Inhibiting mGluR5 activity by AFQ056\/Mavoglurant rescues circuit-specific functional connectivity in Fmr1 knockout mice. Neuroimage. 2019;191:392\u2013402.","journal-title":"Neuroimage."},{"key":"141_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnbeh.2019.00141","volume":"13","author":"P Cogram","year":"2019","unstructured":"Cogram P, Deacon RMJ, Warner-Schmidt JL, von Schimmelmann MJ, Abrahams BS, During MJ. Gaboxadol normalizes behavioral abnormalities in a mouse model of fragile X syndrome. Front Behav Neurosci. 2019;13:1\u20139.","journal-title":"Front Behav Neurosci."},{"key":"141_CR16","doi-asserted-by":"crossref","first-page":"190","DOI":"10.25100\/cm.v45i4.1810","volume":"45","author":"W Saldarriaga","year":"2014","unstructured":"Saldarriaga W, Tassone F, Gonz\u00e1lez-Teshima LY, Forero-Forero JV, Ayala-Zapata SHR. Fragile X syndrome. Colomb Med. 2014;45:190\u20138.","journal-title":"Colomb Med."},{"key":"141_CR17","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1093\/nar\/gkf434","volume":"30","author":"R Pietrobono","year":"2002","unstructured":"Pietrobono R. Quantitative analysis of DNA demethylation and transcriptional reactivation of the FMR1 gene in fragile X cells treated with 5-azadeoxycytidine. Nucleic Acids Res. 2002;30:3278\u201385.","journal-title":"Nucleic Acids Res."},{"key":"141_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13072-016-0060-x","volume":"9","author":"E Tabolacci","year":"2016","unstructured":"Tabolacci E, Mancano G, Lanni S, Palumbo F, Goracci M, Ferr\u00e8 F, et al. Genome-wide methylation analysis demonstrates that 5-aza-2-deoxycytidine treatment does not cause random DNA demethylation in fragile X syndrome cells. Epigenetics Chromatin. 2016;9:1\u201315.","journal-title":"Epigenetics Chromatin."},{"key":"141_CR19","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1038\/sj.onc.1205699","volume":"21","author":"JK Christman","year":"2002","unstructured":"Christman JK. 5-azacytidine and 5-aza-2\u2032-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002;21:5483\u201395.","journal-title":"Oncogene."},{"key":"141_CR20","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.celrep.2019.02.026","volume":"26","author":"D Vershkov","year":"2019","unstructured":"Vershkov D, Fainstein N, Suissa S, Golan-Lev T, Ben-Hur T, Benvenisty N. FMR1 reactivating treatments in Fragile X iPSC-derived neural progenitors in vitro and in vivo. Cell Rep. 2019;26:2531\u20139.e4.","journal-title":"Cell Rep."},{"key":"141_CR21","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1093\/hmg\/8.12.2317","volume":"8","author":"P Chiurazzi","year":"1999","unstructured":"Chiurazzi P, Pomponi MG, Pietrobono R, Bakker CE, Neri G, Oostra BA. Synergistic effect of histone hyperacetylation and DNA demethylation in the reactivation of the FMR1 gene. Hum Mol Genet. 1999;8:2317\u201323.","journal-title":"Hum Mol Genet."},{"key":"141_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/3582601","volume":"2017","author":"AA Dolskiy","year":"2017","unstructured":"Dolskiy AA, Pustylnyak VO, Yarushkin AA, Lemskaya NA, Yudkin DV. Inhibitors of histone deacetylases are weak activators of the FMR1 gene in fragile X syndrome cell lines. Biomed Res Int. 2017;2017:1\u20136.","journal-title":"Biomed Res Int."},{"key":"141_CR23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.5582\/irdr.2016.01048","volume":"5","author":"R Lozano","year":"2016","unstructured":"Lozano R, Azarang A, Wilaisakditipakorn T, Hagerman RJ. Fragile X syndrome: a review of clinical management. Intractable Rare Dis Res. 2016;5:145\u201357.","journal-title":"Intractable Rare Dis Res."},{"key":"141_CR24","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s12035-014-8770-1","volume":"51","author":"T Liu","year":"2015","unstructured":"Liu T, Wan RP, Tang LJ, Liu SJ, Li HJ, Zhao QH, et al. A microRNA profile in Fmr1 knockout mice reveals microRNA expression alterations with possible roles in fragile X syndrome. Mol Neurobiol. 2015;51:1053\u201363.","journal-title":"Mol Neurobiol."},{"key":"141_CR25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.neuron.2010.01.005","volume":"65","author":"D Edbauer","year":"2010","unstructured":"Edbauer D, Neilson JR, Foster KA, Wang C-F, Seeburg DP, Batterton MN, et al. Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132. Neuron. 2010;65:373\u201384.","journal-title":"Neuron."},{"key":"141_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0217275","volume":"14","author":"B DeMarco","year":"2019","unstructured":"DeMarco B, Stefanovic S, Williams A, Moss KR, Anderson BR, Bassell GJ, et al. FMRP\u2014G-quadruplex mRNA\u2014miR-125a interactions: implications for miR-125a mediated translation regulation of PSD-95 mRNA. PLoS ONE. 2019;14:1\u201324.","journal-title":"PLoS ONE."},{"key":"141_CR27","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/ncb1104-1048","volume":"6","author":"P Jin","year":"2004","unstructured":"Jin P, Alisch RS, Warren ST. RNA and microRNAs in fragile X mental retardation. Nat Cell Biol. 2004;6:1048\u201353.","journal-title":"Nat Cell Biol."},{"key":"141_CR28","doi-asserted-by":"crossref","first-page":"E6553","DOI":"10.1073\/pnas.1514260112","volume":"112","author":"JA Suhl","year":"2015","unstructured":"Suhl JA, Muddashetty RS, Anderson BR, Ifrim MF, Visootsak J, Bassell GJ, et al. A 3\u2032 untranslated region variant in FMR1 eliminates neuronal activity-dependent translation of FMRP by disrupting binding of the RNA-binding protein HuR. Proc Natl Acad Sci. 2015;112:E6553\u201361.","journal-title":"Proc Natl Acad Sci."},{"key":"141_CR29","doi-asserted-by":"crossref","unstructured":"Lin S. MicroRNAs and Fragile X Syndrome. In: Santulli G, editor. MicroRNA: Medical Evidence. From Molecular Biology to Clinical Practice. 1st ed. Switzerland: Springer International Publishing; 2015. p. 107\u201321.","DOI":"10.1007\/978-3-319-22671-2_7"},{"key":"141_CR30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.lfs.2018.12.008","volume":"218","author":"C Wang","year":"2019","unstructured":"Wang C, Ge L, Wu J, Wang X, Yuan L. MiR-219 represses expression of dFMR1 in Drosophila melanogaster. Life Sci. 2019;218:31\u20137.","journal-title":"Life Sci."},{"key":"141_CR31","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1080\/15476286.2015.1063770","volume":"12","author":"P Han","year":"2015","unstructured":"Han P, Chang CP. Long non-coding RNA and chromatin remodeling. RNA Biol. 2015;12:1094\u20138.","journal-title":"RNA Biol."},{"key":"141_CR32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00439-013-1356-6","volume":"133","author":"C Pastori","year":"2014","unstructured":"Pastori C, Peschansky VJ, Barbouth D, Mehta A, Silva JP, Wahlestedt C. Comprehensive analysis of the transcriptional landscape of the human FMR1 gene reveals two new long noncoding RNAs differentially expressed in Fragile X syndrome and Fragile X-associated tremor\/ataxia syndrome. Hum Genet. 2014;133:59\u201367.","journal-title":"Hum Genet."},{"key":"141_CR33","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","volume":"16","author":"R Rupaimoole","year":"2017","unstructured":"Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203\u201321.","journal-title":"Nat Rev Drug Discov."},{"key":"141_CR34","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","volume":"79","author":"SM Hoy","year":"2019","unstructured":"Hoy SM. Onasemnogene abeparvovec: first global approval. Drugs. 2019;79:1255\u201362.","journal-title":"Drugs."},{"key":"141_CR35","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2174\/1566524013363492","volume":"1","author":"I Gantois","year":"2001","unstructured":"Gantois I, Bakker C, Reyniers E, Willemsen R, DHooge R, De Deyn P, et al. Restoring the phenotype of fragile X syndrome: insight from the mouse model. Curr Mol Med. 2001;1:447\u201355.","journal-title":"Curr Mol Med."},{"key":"141_CR36","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.expneurol.2006.08.007","volume":"203","author":"SA Musumeci","year":"2007","unstructured":"Musumeci SA, Calabrese G, Bonaccorso CM, D\u2019Antoni S, Brouwer JR, Bakker CE, et al. Audiogenic seizure susceptibility is reduced in fragile X knockout mice after introduction of FMR1 transgenes. Exp Neurol. 2007;203:233\u201340.","journal-title":"Exp Neurol."},{"key":"141_CR37","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/hmg\/9.8.1145","volume":"9","author":"AM Peier","year":"2000","unstructured":"Peier AM, McIlwain KL, Kenneson A, Warren ST, Paylor R, Nelson DL. (Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. Hum Mol Genet. 2000;9:1145\u201359.","journal-title":"Hum Mol Genet."},{"key":"141_CR38","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/gt.2009.83","volume":"16","author":"Z Zeier","year":"2009","unstructured":"Zeier Z, Kumar A, Bodhinathan K, Feller JA, Foster TC, Bloom DC. Fragile X mental retardation protein replacement restores hippocampal synaptic function in a mouse model of fragile X syndrome. Gene Ther. 2009;16:1122\u20139.","journal-title":"Gene Ther."},{"key":"141_CR39","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1038\/npp.2014.167","volume":"39","author":"S Gholizadeh","year":"2014","unstructured":"Gholizadeh S, Arsenault J, Xuan IC, Pacey LK, Hampson DR. Reduced phenotypic severity following adeno-associated virus-mediated Fmr1 gene delivery in fragile X mice. Neuropsychopharmacology. 2014;39:3100\u201311.","journal-title":"Neuropsychopharmacology."},{"key":"141_CR40","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1089\/hum.2016.090","volume":"27","author":"J Arsenault","year":"2016","unstructured":"Arsenault J, Gholizadeh S, Niibori Y, Pacey LK, Halder SK, Koxhioni E, et al. FMRP expression levels in mouse central nervous system neurons determine behavioral phenotype. Hum Gene Ther. 2016;27:982\u201396.","journal-title":"Hum Gene Ther."},{"key":"141_CR41","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.cell.2018.01.012","volume":"172","author":"XS Liu","year":"2018","unstructured":"Liu XS, Wu H, Krzisch M, Wu X, Graef J, Muffat J, et al. Rescue of fragile X syndrome neurons by DNA methylation editing of the FMR1 gene. Cell. 2018;172:979\u201392.e6.","journal-title":"Cell."},{"key":"141_CR42","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/s41551-018-0252-8","volume":"2","author":"B Lee","year":"2018","unstructured":"Lee B, Lee K, Panda S, Gonzales-Rojas R, Chong A, Bugay V, et al. Nanoparticle delivery of CRISPR into the brain rescues a mouse model of fragile X syndrome from exaggerated repetitive behaviours. Nat Biomed Eng. 2018;2:497\u2013507.","journal-title":"Nat Biomed Eng."},{"key":"141_CR43","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.molmed.2018.07.008","volume":"24","author":"DV Foss","year":"2018","unstructured":"Foss DV, Wilson RC. Emerging strategies for genome editing in the brain. Trends Mol Med. 2018;24:822\u20134.","journal-title":"Trends Mol Med."}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41434-020-0141-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41434-020-0141-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41434-020-0141-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:14:28Z","timestamp":1684617268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-020-0141-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,12]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["141"],"URL":"https:\/\/doi.org\/10.1038\/s41434-020-0141-0","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,12]]},"assertion":[{"value":"25 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}